L. Wood

593 total citations
23 papers, 481 citations indexed

About

L. Wood is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, L. Wood has authored 23 papers receiving a total of 481 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Pulmonary and Respiratory Medicine, 9 papers in Molecular Biology and 8 papers in Oncology. Recurrent topics in L. Wood's work include Renal cell carcinoma treatment (14 papers), Cancer Genomics and Diagnostics (8 papers) and Renal and related cancers (7 papers). L. Wood is often cited by papers focused on Renal cell carcinoma treatment (14 papers), Cancer Genomics and Diagnostics (8 papers) and Renal and related cancers (7 papers). L. Wood collaborates with scholars based in United States, Canada and Australia. L. Wood's co-authors include Brian I. Rini, Paul Elson, J. Garcia, Ronald M. Bukowski, Robert Dreicer, Ila Tamaskar, Kriti Mittal, Yana G. Najjar, Adriana G. Ioachimescu and Tarek Mekhail and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and European Journal of Cancer.

In The Last Decade

L. Wood

21 papers receiving 471 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
L. Wood United States	12	333	254	185	126	55	23	481
I. Chen United States	7	422 1.3×	322 1.3×	234 1.3×	203 1.6×	30 0.5×	9	587
Taizo Hirata Japan	12	285 0.9×	153 0.6×	555 3.0×	145 1.2×	29 0.5×	36	808
Vincenzo Emanuele Chiurì Italy	12	456 1.4×	213 0.8×	478 2.6×	189 1.5×	29 0.5×	35	703
Amit Mehta United States	12	300 0.9×	197 0.8×	183 1.0×	115 0.9×	56 1.0×	18	667
Yoshiko Umeyama Japan	16	554 1.7×	263 1.0×	490 2.6×	146 1.2×	65 1.2×	35	813
Mustapha Chadjaa France	11	542 1.6×	136 0.5×	283 1.5×	240 1.9×	32 0.6×	34	756
Delphine Topart France	12	234 0.7×	122 0.5×	425 2.3×	231 1.8×	35 0.6×	29	606
Milan Mangeshkar United States	9	369 1.1×	217 0.9×	289 1.6×	165 1.3×	86 1.6×	17	655
S. Srinivas United States	13	527 1.6×	410 1.6×	282 1.5×	264 2.1×	25 0.5×	38	816
Marilyn Mulay United States	11	250 0.8×	243 1.0×	365 2.0×	104 0.8×	96 1.7×	17	644

Countries citing papers authored by L. Wood

Since Specialization

Citations

This map shows the geographic impact of L. Wood's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by L. Wood with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites L. Wood more than expected).

Fields of papers citing papers by L. Wood

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by L. Wood. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by L. Wood. The network helps show where L. Wood may publish in the future.

Co-authorship network of co-authors of L. Wood

This figure shows the co-authorship network connecting the top 25 collaborators of L. Wood. A scholar is included among the top collaborators of L. Wood based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with L. Wood. L. Wood is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Guiner, Caroline Le, Thibaut Larcher, Oumeya Adjali, et al.. (2017). Dose finding study in the DMDmdx rat model to determine the efficacious dose of a rAAV9 vector encoding a human mini-dystrophin after IV administration. Neuromuscular Disorders. 27. S188–S188.

Najjar, Yana G., Kriti Mittal, Paul Elson, et al.. (2014). A 2weeks on and 1week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma. European Journal of Cancer. 50(6). 1084–1089. 89 indexed citations

MacKenzie, Mary J., Brian I. Rini, Paul Elson, et al.. (2010). Temsirolimus in VEGF-refractory metastatic renal cell carcinoma. Annals of Oncology. 22(1). 145–148. 46 indexed citations

Khan, Gazala, Ali Golshayan, Paul Elson, et al.. (2010). Sunitinib and sorafenib in metastatic renal cell carcinoma patients with renal insufficiency. Annals of Oncology. 21(8). 1618–1622. 45 indexed citations

Wood, L., et al.. (2010). Sunitinib Causes Macrocytosis in Patients with Advanced Renal Cell Carcinoma. Current Oncology. 17(2). 30–33. 8 indexed citations

Garcia, Jacob, G. R. Hudes, Toni K. Choueiri, et al.. (2009). 7108 Phase II study of IMC-1121B in patients with metastatic renal cell carcinoma (mRCC) following failure of VEGFR-2 tyrosine kinase inhibitor (TKI) therapy: interim results (IMCL CP12–0605/NCT00515697). European Journal of Cancer Supplements. 7(2). 425–425. 13 indexed citations

Olencki, Thomas, L. Wood, Lisa Rybicki, et al.. (2007). Gene Modulatory Effects, Pharmacokinetics, and Clinical Tolerance of Interferon-α1b: A Second Member of the Interferon-α Family. Clinical Pharmacology & Therapeutics. 81(3). 354–361. 14 indexed citations

Tamaskar, Ila, Ronald M. Bukowski, Paul Elson, et al.. (2007). Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib. Annals of Oncology. 19(2). 265–268. 114 indexed citations

Choueiri, Toni K., Brian I. Rini, Robert Dreicer, et al.. (2007). Macrocytosis in patients with metastatic renal cell carcinoma (mRCC) treated with tyrosine kinase inhibitors (TKI's). Journal of Clinical Oncology. 25(18_suppl). 15583–15583. 1 indexed citations

10.

Tamaskar, Ila, J. Garcia, Robert Dreicer, et al.. (2007). Thyroid function test (TFT) abnormalities in patients (pts) with metastatic renal cell carcinoma (RCC) treated with sorafenib. Journal of Clinical Oncology. 25(18_suppl). 5048–5048. 5 indexed citations

11.

George, Saby, Amy L. Richmond, Paul Elson, et al.. (2007). WBC changes as a pharmacodynamic marker of outcome in metastatic renal cell carcinoma (mRCC) patients (Pts) receiving sunitinib. Journal of Clinical Oncology. 25(18_suppl). 5043–5043. 5 indexed citations

12.

Tamaskar, Ila, Philip Shaheen, L. Wood, et al.. (2006). Antitumor effects of sorafenib and sunitinib in patients (pts) with metastatic renal cell carcinoma (mRCC) who had prior therapy with anti-angiogenic agents. Journal of Clinical Oncology. 24(18_suppl). 4597–4597. 21 indexed citations

13.

Shaheen, Philip, Ila Tamaskar, Brian I. Rini, et al.. (2006). Thyroid function tests (TFTs) abnormalities in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib. Journal of Clinical Oncology. 24(18_suppl). 4605–4605. 20 indexed citations

14.

Finke, James H., Brian I. Rini, Amy L. Richmond, et al.. (2006). T regulatory cells (Treg) in patients with metastatic renal cell carcinoma (mRCC) decrease during sunitinib treatment: Correlations with clinical responses and T helper 1/T helper 2 (Th1/Th2) bias. Journal of Clinical Oncology. 24(18_suppl). 2526–2526. 15 indexed citations

15.

Schwartz, Gary N., Monica Mita, K. Papadopoulos, et al.. (2005). A pilot, pharmacokinetic (PK), and pharmacodynamic (PD) study to determine the feasibility of intrapatient dose escalation to tolerable rash and the activity of maximal doses of erlotinib (E) in previously treated patients with advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 23(16_suppl). 3045–3045. 8 indexed citations

16.

Holen, Kyle D., Samira Syed, Alison L. Hannah, et al.. (2004). Phase I study using continuous intravenous (CI) KOS-862 (Epothilone D) in patients with solid tumors. Journal of Clinical Oncology. 22(14_suppl). 2024–2024. 23 indexed citations

17.

Olencki, Thomas, David M. Peereboom, L. Wood, et al.. (2001). Phase I and II trials of subcutaneously administered rIL-2, interferon alfa-2a, and fluorouracil in patients with metastatic renal carcinoma. Journal of Cancer Research and Clinical Oncology. 127(5). 319–324. 12 indexed citations

18.

Budd, G. Thomas, et al.. (1999). Approaches to managing carboplatin-induced thrombocytopenia: focus on the role of amifostine.. PubMed. 26(2 Suppl 7). 41–50. 19 indexed citations

19.

Stewart, Charles A., et al.. (1990). Bone Scan of Recurrent Colon Carcinoma Involving the Sacrum and Urinary Bladder. Clinical Nuclear Medicine. 15(7). 513–514. 1 indexed citations

20.

Jacobs, P, et al.. (1989). Hydroxyurea hypersensitivity reaction.. PubMed. 75(10). 506–506. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact